Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Active not recruiting 3Recruiting 2

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5

Conditions

Multiple Myeloma 61Neoplasms 7Neoplasms, Plasma Cell 6Recurrence 5Hematologic Neoplasms 4Renal Insufficiency 3Paraproteinemias 3Lymphoma 3Immunoglobulin Light-chain Amyloidosis 3Hematologic Diseases 3Smoldering Multiple Myeloma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms by Histologic Type 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Acute 2Leukemia 2Blood Protein Disorders 2Purpura 1Prostatic Neoplasms 1Neoplasm, Residual 1Nausea 1Natural Killer/T-cell Lymphoma 1Monoclonal Gammopathy of Undetermined Significance 1Macroglossia 1Lymphoproliferative Disorders 1Lymphoma, Large B-Cell, Diffuse 1Lymphadenopathy 1Leukemia, Plasma Cell 1Immunoproliferative Disorders 1

Interventions

Cyclophosphamide 151Dexamethasone 140Rituximab 83fludarabine 78Cytarabine 69Lenalidomide 68Bortezomib 63fludarabine phosphate 62Gemcitabine 62venetoclax 54Etoposide 53pembrolizumab 52pomalidomide 48Paclitaxel 48Cisplatin 47Carboplatin 47Peripheral Blood Stem Cell Transplantation 46Filgrastim 40Radiotherapy 39Calcium Dobesilate 36Busulfan 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 29Vincristine 28Temozolomide 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Recurrence × isatuximab × Clear all
NCT05911321 2026-05-20

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

UNC Lineberger Comprehensive Cancer Center

Phase 2 Active not recruiting
6 enrolled 5 charts
Plasma cell

Multiple Myeloma, Recurrence

NCT06832865 2026-03-12

ELISA in Relapsed/Refractory MM

Massachusetts General Hospital

Phase 2 Recruiting
30 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT05922501 2026-01-14

ISABELA

Massachusetts General Hospital

Phase 2 Recruiting
50 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT02332850 2025-05-01

Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma

University of California, San Francisco

Phase 1 Active not recruiting
83 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT03989414 2024-11-29

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Celgene

Phase 1/2 Active not recruiting
424 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡